4D Molecular Therapeutics, Inc. (FDMT) income statement
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3017% below fair value
$10.46−0.33 (-3.06%)
Close on Nov 18, 2026Market cap $755.00MP/E –Yield –
4D Molecular Therapeutics, Inc. financial ratios
See a number that looks wrong?